Store
World Market for Blood Screening, 2022
Publication Date: January 5, 2022
Tags: COVID-19, Diagnostic Instruments, Hematology, Immunoassay, Infectious Diseases
Pages: 40
SKU: 22-052
Kalorama Information presents a comprehensive analysis of the evolving global blood screening market in its latest report, World Market for Blood Screening, 2022. This multibillion-dollar market is crucial for ensuring the safety of the blood supply by detecting infectious diseases and conditions. The report provides insights into market dynamics, technological advancements, and regional developments, making it an essential resource for stakeholders in the blood screening industry.
Report Highlights:
- Market Overview:
- Blood screening is a critical medical process for detecting pathogens in donated blood, particularly in developed nations.
- The market, though mature, is experiencing growth driven by new technologies, increased testing volumes, and expansion in developing nations.
- Primary Objectives of Blood Screening Testing:
- Monitoring the emergence of new infectious agents in the blood supply.
- Determining causes of transfusion reactions with unknown etiology.
- Assessing the effectiveness of new donor screening methods.
- Evaluating and improving the blood donation process to ensure an adequate supply.
- Key Market Drivers:
- The aging population in developed markets.
- New test applications enhancing diagnostic capabilities.
- Significant growth potential in emerging markets as developing nations implement stricter blood safety measures, particularly through Nucleic Acid Testing (NAT).
Table: Global Blood Typing Sales Distribution, by Region, 2021 (%)
| Region | % Mkt |
| North America | XX% |
| Europe | XX% |
| Asia Pacific | XX% |
| RoW | XX% |
Source: Kalorama Information
For further details and to purchase directly, please contact us.
Table of Contents
CHAPTER 1: EXECUTIVE SUMMARY
OVERVIEW OF BLOOD SCREENING DIAGNOSTICS
MARKET OUTLOOK
-
- Figure 1-1: Blood Donation Screening Market Distribution by Analyte, 2021
-
- Figure 1-2: Whole Blood Donations per 1000 Population, 2013
- Major Product Activity
- Immunoassay
CHAPTER 2: BLOOD SCREENING MARKET
-
- Figure 2-1: Blood Screening Market, 2016 – 2026 ($B)
-
- Figure 2-2: Policy Adoption of NAT for Blood Screening of HCV, HBV and HIV by Select Country
IMMUNOASSAY AND NUCLEIC ACID TESTING (NAT) MARKETS
-
- Figure 2-3: Blood Screening Sales by Test Method (Immunoassay vs. NAT), 2021 and 2026 ($B)
REGIONAL MARKET
-
- Table 2-1: Blood Screening Market Distribution by Global Region, 2021 (North America, Europe, Asia Pacific, RoW)
-
- Table 2-2: Laboratory Screening of Blood Donations for Transfusion-Transmissible Infections, Number of Countries (Syphilis, HCV, HBV, HIV, Chagas, Malaria, HTLV I/II)
-
- Table 2-3: Prevalence of TTIs in Blood Donations [Median (Interquartile range)], by Income Group
OTHER TRENDS
COVID-19
- Zika Virus
- Blood and Component Collection
- Table 2-4: Blood Component Usage for Selected Conditions
- Table 2-5: Red Blood Cell and Platelet Use by Hospital Services (%)
COVID-19 Impact on Plasma Collection
- Reevaluating Blood Transfusions
- Table 2-6: Impact of Alloimmunization (% of Patients Screening Positive for One or More Antibodies)
CHAPTER 3: BLOOD TYPING AND GROUPING MARKET
- Manual Blood Typing Methods
- Automated Blood Typing and Screening Methods
- Molecular Methods
- Reducing Blood Typing Errors
- Table 3-1: Selected Blood Typing and Grouping Innovations
Size and Growth of Typing Markets
-
- Table 3-2: Global Blood Typing Market, 2021-2026 (Typing) (in $ millions)
Blood Typing Market by Geography
-
- Table 3-3: Global Blood Typing Sales Distribution by Region, 2021 (%) (North America, Europe, Asia Pacific, RoW)
CHAPTER 4: TOP COMPANY BRIEFS
- ABBOTT DIAGNOSTICS
- CERUS CORPORATION
- COVID-19
- GRIFOLS S.A.
- ORTHO CLINICAL DIAGNOSTICS (ORTHO)
- Blood Bank
- Avioq and Ortho Clinical
QUOTIENT LIMITED
- COVID-19
ROCHE
- Blood Bank
Related products
Molecular Diagnostics in Oncology, Genetic/Inherited Diseases, and NIPT, 2023-2028
November 29, 2023
In recent decades, genetic technologies for research and diagnostics have transformed healthcare, offering new possibilities in precision medicine and disease management. Next-generation sequencing (NGS) has revolutionized genetic disease diagnostics and oncology, providing comprehensive insights at a relatively low cost. PCR continues to evolve, remaining a central tool in molecular diagnostics. In situ hybridization techniques (ISH)…
$5,000.00 – $7,500.00
Cell and Gene Therapy Deals Analysis, 2021-2024
June 3, 2024
Kalorama Information’s Cell and Gene Therapy Deals Analysis: Financings, Partnering, M&A, Tech Transfers, IPOs/SPACs, Other Deals, 2021-2024 offers a comprehensive look at the dynamic and rapidly evolving cell and gene therapy market. This report highlights the significant deal-making activities that have taken place from Q1 2021 to Q1 2024, providing valuable insights for companies and…
$6,300.00 – $9,450.00
Cell Therapy and Gene Therapy Disease Markets, 2023-2029
April 30, 2024
Explore the future of medicine with our in-depth report on cell therapy, gene therapy, and RNA therapy markets. Cell therapy and gene therapy represent a frontier in modern medicine, promising revolutionary treatments by treating the underlying genetic causes of disease and by genetically controlling the body’s immune system. Recent years have seen an increase in…
$5,000.00 – $7,875.00
